Literature DB >> 16803862

Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors.

John W Ryder1, Julie F Falcone, Jason R Manro, Kjell A Svensson, Kalpana M Merchant.   

Abstract

The biarylpropylsulfonamide class of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) potentiators represented by N-2-(4-(4-cyanophenol)phenol)propyl-2-propanesulfonamide (LY404187) and (R)-4'-[1-fluoro-1-methyl-2-(propane-2-sulfonylamino)-ethyl]-biphenyl-4-carboxylic acid methylamide (LY503430) are positive, allosteric AMPA receptor activators, which enhance AMPA receptor-mediated neurotransmission by reducing desensitization of the ion channel. Although these compounds have efficacy in in vivo rodent models of cognition, depression, and Parkinson's disease, little is known about biochemical pathways activated by these agents. Given the well established regulation of the nitric oxide/cGMP pathway by excitatory neurotransmission, the current study characterized AMPA receptor potentiator-mediated cGMP response in mouse cerebellum. Acute treatment by both LY404187 and LY503430 [2.0, 5.0, or 10 mg/kg subcutaneously (s.c.)] elevated basal cerebellar cGMP levels in a dose-dependent manner. Pretreatment with the noncompetitive, allosteric AMPA receptor-selective antagonist 7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-7-carboxamide, 5-(4-aminophenyl)-8,9-dihydro-N,8-dimethyl-monohydrochloride-(9CI) (GYKI 53655) [3.0 mg/kg intraperitoneally (i.p.)], completely blocked the effect of LY404187, demonstrating that activation of AMPA receptors induces cGMP levels. Interestingly, pretreatment with the N-methyl-d-aspartate (NMDA) open channel blocker dizocilpine (0.3 and 1.0 mg/kg i.p.) also abolished the AMPA receptor potentiator-mediated cGMP accumulation, indicating that activation of AMPA receptors leads to NMDA receptor-mediated transmission involved in cGMP regulation. Pharmacological augmentation of the endogenous glutamate tone via the alkaloid harmaline (20-60 mg/kg i.p.) synergized with AMPA potentiator activity and provided further direct evidence of in vivo allosteric activation of AMPA receptors by LY404187. The synergism between harmaline and LY404187 was specific, since cGMP accumulation induced by foot-shock stress was not augmented by the AMPA receptor potentiator. Taken together, these data indicate that the cGMP system may play an important role in pharmacological efficacy of the biarylpropylsulfonamide class of AMPA receptor potentiators.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16803862     DOI: 10.1124/jpet.106.105734

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

1.  Riluzole Ameliorates Harmaline-induced Tremor in Rat.

Authors:  Fatemeh Rahimi Shourmasti; Iran Goudarzi; Kataneh Abrari; Mahmoud Elahdadi Salmani; Taghi Laskarbolouki
Journal:  Basic Clin Neurosci       Date:  2014

2.  Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors.

Authors:  Jeffrey M Witkin; Linda M Rorick-Kehn; Mark J Benvenga; Benjamin L Adams; Scott D Gleason; Karen M Knitowski; Xia Li; Steven Chaney; Julie F Falcone; Janice W Smith; Julie Foss; Kirsti Lloyd; John T Catlow; David L McKinzie; Kjell A Svensson; Vanessa N Barth; Miguel A Toledo; Nuria Diaz; Celia Lafuente; Alma Jiménez; Alfonso Benito; Conception Pedregal; Maria A Martínez-Grau; Anke Post; Michael A Ansonoff; John E Pintar; Michael A Statnick
Journal:  Pharmacol Res Perspect       Date:  2016-11-07

Review 3.  Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road.

Authors:  Bashkim Kadriu; Laura Musazzi; Jenessa N Johnston; Lisa E Kalynchuk; Hector J Caruncho; Maurizio Popoli; Carlos A Zarate
Journal:  Drug Discov Today       Date:  2021-08-03       Impact factor: 8.369

4.  Functional Antagonism of Sphingosine-1-Phosphate Receptor 1 Prevents Harmaline-Induced Ultrastructural Alterations and Caspase-3 Mediated Apoptosis.

Authors:  Narjes Dahmardeh; Mohammad Shabani; Mohsen Basiri; Taj Pari Kalantaripour; Majid Asadi-Shekaari
Journal:  Malays J Med Sci       Date:  2019-08-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.